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Abstract: Sarcoidosis is a systemic inflammatory condition with an unexplained predilection 
for the lung: over 90% of patients have radiographic or physiological abnormalities. Respiratory 
physicians therefore often manage patients, but any organ may be involved, with noncaseating 
granulomas the characteristic feature. Sarcoidosis is the commonest interstitial lung disease 
(ILD), differing from most other ILDs in that many patients remain asymptomatic or improve 
spontaneously. Careful baseline assessment of disease distribution and severity is thus central 
to initial management. Subsequently, the unpredictable clinical course necessitates regular 
monitoring. Sarcoidosis occurs worldwide, with a high prevalence in Afro-Caribbeans and 
those of Swedish or Danish origin. African Americans also tend to have severe disease. Oral 
corticosteroids have been used since the 1950s, with evidence of short to medium response; more 
recent studies have examined the role of inhaled steroids. Long-term benefits of steroids remain 
uncertain. International guidelines published in 1999 represent a consensus view endorsed by 
North American and European respiratory societies. Updated British guidelines on interstitial 
lung disease, including sarcoidosis, were published in 2008. This review describes current 
management strategies for pulmonary disease, including oral and inhaled steroids, commonly 
used alternative immunosuppressant agents, and lung transplantation. Tumor necrosis factor 
alpha inhibitors are briefly discussed.
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Introduction
Sarcoidosis is the commonest form of interstitial lung disease (ILD). It affects men and 
women of all races around the world, typically aged 20 to 40. Prevalence varies with 
geography: reported figures range from 1.33 (in White European populations) to 47 
(in African American populations) per 100,000 in North America, and 64 per 100,000 
in Scandinavia.1,2 A registry-based Danish study reported an overall incidence of 7.2 
per 100,000 person years.3 A recent British study concluded that overall incidence rate 
was 5.0 per 100,000 person-years, being highest in London, the West Midlands and 
Northern Ireland, and that incidence had remained stable between 1991 and 2003.4 
In addition to having a high prevalence of sarcoidosis, Blacks and Afro-Caribbeans 
also suffer more severe disease. The cause of sarcoidosis remains unknown, but genetic 
factors affect susceptibility and prognosis.
Diagnosis
Multiple organ involvement is typical. The sarcoidosis phenotype differs between 
populations, but the ACCESS study showed that, in a large North American cohort, Therapeutics and Clinical Risk Management 2009:5 576
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the most commonly affected organs are the lungs, skin, lymph 
nodes, eyes and liver.5 The lungs are involved in over 90% 
of patients, who are therefore often seen by a respiratory 
specialist in the first instance. Presentation is highly variable, 
depending on the pattern of organ involvement and speed 
of onset, and there is no single specific or sensitive diag-
nostic test. Diagnosis therefore depends on establishing 
a consistent clinical picture, noting symptoms, signs and 
characteristic clinical features such as consistent radiological 
and physiological abnormalities, excluding other differential 
diagnoses (in particular tuberculosis and lymphoma), and on 
demonstrating the presence of noncaseating granulomas in 
one or more affected organs.
Radiological appearances
Pulmonary sarcoidosis is traditionally classified by chest 
radiograph (CXR) appearances, as originally proposed 
by Scadding. Although increasingly being supplanted by 
more sensitive and detailed imaging modalities such as 
high resolution computed tomography (HRCT) scanning, 
the CXR stages 0–IV have the merit of modest correlation 
with prognosis (Table 1). Spontaneous resolution occurs 
in 55% to 90% of patients with stage I disease, 40% to 70% 
with stage II disease, and 10% to 20% with stage III disease. 
Fibrosis is not reversible, even with treatment, and may 
be associated with the development of bronchiectasis and 
aspergillomas. The CXR is thus an important part of initial 
evaluation and assists in guiding treatment decisions.
The inflammatory response
The inflammatory response is characterized by activated 
macrophages and CD4 helper T lymphocytes, with a pattern 
of cytokine production most consistent with a Th1-type 
immune response triggered by antigen. Depressed cutane-
ous delayed-type hypersensitivity explains the typically 
negative tuberculin test. T cell receptor (TCR) studies sug-
gest the existence of a population of T cells with restricted 
TCR usage, suggesting that a specific antigen triggers the 
disease. It is relevant to novel therapeutic strategies that 
tumor necrosis factor alpha (TNFα) up-regulates endothelial 
cell adhesion molecules involved in leukocyte binding, 
stimulates T lymphocyte release of interferon gamma 
(IFNγ), and enhances T lymphocyte proliferation. The 
net result is amplification of the steps involved in antigen 
recognition, cytokine release, inflammatory cell recruitment 
and granuloma formation.
General management strategies
Clear communication to patients about diagnosis and 
management is vital, given clinical and scientific uncertainties 
around the cause of the condition, treatment and prognosis, 
and the abundance of poor quality and sensationalist 
information available on the internet. Many North American, 
European and British professional societies and major 
charities now provide excellent patient information leaflets 
which can readily be downloaded from their websites.
Although patients with pulmonary sarcoidosis are less 
likely to smoke than their peers, the disease is not less severe 
in smokers6 and respiratory professionals agree that smoking 
cessation advice should be offered to all patients. While there 
are no randomized controlled trials of pulmonary rehabilita-
tion in sarcoidosis, patients with pulmonary fibrosis causing 
deconditioning, disabling breathlessness, impaired quality 
of life, nutritional deficits, fatigue and social isolation share 
many features in common with those suffering from chronic 
obstructive pulmonary disease (COPD), and should be 
considered for pulmonary rehabilitation. Sarcoidosis patients 
with pulmonary fibrosis who fulfil criteria for supplemental 
oxygen, whether ambulatory or long-term, should be assessed 
and managed according to national guidelines. Palliative care 
may be appropriate in a minority of patients when all other 
forms of treatment have been exhausted.
Treatment with oral corticosteroids
There are no clear criteria for initiating corticosteroid therapy 
for pulmonary disease. Spontaneous remission occurs in up to 
90% of patients; the natural history is variable; the long-term 
effects of treatment remain unclear; and there are important 
potential adverse effects of steroid treatment.7,8 However, the 
value of oral corticosteroids in pulmonary sarcoidosis was 
first reported in the 1950s,9 and they have been widely used 
since the 1960s. An early study in a small series showed that 
a short course of adrenocorticotrophin hormone (ACTH) 
or cortisone attenuated infiltrates seen on CXR, and that 
prolonged cortisone treatment led to remission of granulomas 
in repeat biopsy samples.10 Both uncontrolled and controlled 
studies have confirmed clinicians’ observations of short to 
Table 1 Chest radiograph appearances in sarcoidosis
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medium term (weeks to months) symptomatic, radiographic 
and functional improvement. Even in patients with chronic 
disease previously untreated for several years, oral steroids 
can have short-term clinical value.11
The long-term benefits of oral steroid treatment, in 
particular whether they prevent pulmonary fibrosis and/or 
improve survival, remain unclear,12 with most studies 
showing no clear advantage. The numbers of patients in 
such studies ranges from 17 to 172, and interpretation is 
complex because of differences in disease phenotype, with 
some patients showing spontaneous regression and varying 
degrees of residual scarring, while others develop persistent 
disease. Significant long-term disability caused by pulmonary 
fibrosis is estimated to arise in 3% to 20%.13
Inclusion in these studies of patients with stage I dis-
ease on CXR is contentious because of the high rate of 
spontaneous resolution in this group. In most series steroids 
were started when patients presented, whereas in reality most 
respiratory specialists delay treatment in favor of careful 
monitoring. Most studies used a treatment protocol which 
did not include gradual tapering of the dose according to 
response, although this is also common clinical practice. 
Ethnic variation is another important consideration: most 
North American studies included a large proportion of black 
and Afro-Caribbean patients in whom sarcoidosis is often 
more severe. Their results may therefore not be applicable 
to European populations.
The British Thoracic Society (BTS) open label study14 
attempted to model real-life practice more closely by 
including a 6-month observation period before starting oral 
corticosteroid treatment. Patients in whom there was no 
evidence of spontaneous improvement after this time were 
started on treatment. These patients were then alternately 
allocated to one of two groups. One group were treated with 
steroids for at least 18 months (prednisolone 30 mg daily 
for 1 month, reducing by 5 mg every month to a mainte-
nance dose of 10 mg daily) with the aim of achieving and 
maintaining maximal radiographic improvement; while in the 
second group treatment was limited to alleviating symptoms 
or managing deteriorating lung function. Patients were fol-
lowed up for 5 years.
Patients in the first group showed greater improvements 
in symptoms, lung function and radiographic appearances 
than those in the second group. Average difference in 
vital capacity at the concluding review was 9% predicted. 
Of the 149 subjects recruited, 58 (39%) showed spontaneous 
radiographic resolution after six months and 33 (22%) 
needed steroids for symptoms. Most patients were white. 
Side-effects of treatment were frequent but mostly mild, 
leading to withdrawal in only two patients.
Symptom relapse on reducing or withdrawing steroids is 
well-recognised. A retrospective study15 showed that relapse 
occurred more often in patients previously treated with steroids 
than in those who had experienced spontaneous resolution. 
The authors argued that steroid treatment itself could have con-
tributed to disease prolongation. However most of the patients 
in this study were treated for extra-pulmonary disease, most 
were blacks and Afro-Caribbeans, and those experiencing 
spontaneous remission had milder disease initially. This 
question therefore needs addressing in a prospective study. 
Current UK guidelines on pulmonary sarcoidosis16 conclude 
that we still do not know whether steroid treatment has a 
negative effect on longer-term prognosis.
A recent systematic review of steroid treatment in pul-
monary sarcoidosis17 included data from eight studies. Of 
150 available studies, these were the only ones meeting the 
inclusion criteria and considered to contain valid data. Six 
studies examined oral steroids alone, one study used oral 
steroids then inhaled steroids, and one examined inhaled ste-
roids alone. The authors concluded that oral corticosteroids 
improve CXR appearances after 6 to 24 months of treatment 
and result in small increases in vital capacity and diffusing 
capacity, although it is unclear whether these benefits persist 
after 2 years. These observations support the widespread view 
that steroids are not indicated in stage I disease unless lung 
function is declining. The authors commented that there are 
no data suggesting that steroid treatment influences long-term 
disease progression.
The starting dose of prednisolone in controlled studies 
has varied from 30 mg to 60 mg daily, usually tapering each 
month according to response, to an average of 10 mg daily 
maintained for 6 to 12 months before attempting slow with-
drawal. Anecdotal observation suggests that in some patients, 
treatment is best continued for at least two years to prevent 
relapses. Alternate day dosing (with the dose kept equivalent 
to the average daily dose) has been suggested to limit side-
effects18 and shown in a controlled study to be as effective 
as daily treatment.19 Such a regime is not always practical: 
diabetic patients may prefer daily dosing to maintain glucose 
control, and those who have difficulty remembering to take 
treatment may choose a once daily protocol.
Treatment with inhaled 
corticosteroids
Selroos and colleagues first reported the value of inhaled 
budesonide in an open study of 20 patients with pulmonary Therapeutics and Clinical Risk Management 2009:5 578
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sarcoidosis.20 Several later studies investigated the potential 
of inhaled steroids, either as first-line treatment or as mainte-
nance after a response has been obtained with oral steroids. 
Only two studies, using budesonide, showed benefit.
A more recent study21 compared outcomes after three 
months of prednisone followed by 15 months of inhaled 
budesonide with placebo. Corticosteroid therapy was of 
benefit, especially for those with parenchymal disease, and 
the benefit persisted for five years after stopping treatment.22 
In the systematic review already mentioned,17 inhaled corti-
costeroid trials were small and the results inconclusive.
Taken together, current evidence thus suggests that 
inhaled steroids are less consistently effective than oral 
steroids in pulmonary sarcoidosis. This is unsurprising since 
they target the airways rather than the lung parenchyma, 
and it is generally agreed they should not be employed rou-
tinely.23 They may have a role in maintenance treatment, or as 
steroid-sparing agents; they may also be of value in patients 
whose main symptom is cough and/or who have evidence 
of endobronchial involvement.
Adverse effects of steroids
A number of recent studies indicate that adverse events such 
as weight gain, skin thinning, sleep disturbance, osteoporosis 
and neuropsychiatric disorders occur not infrequently in 
patients taking corticosteroids, even in low dose.24 They 
appear to depend on dose and duration of treatment, and 
recent data reinforce previous observations suggesting that 
glucocorticosteroids significantly increase the risk of infec-
tion. Steroid-induced diabetes is also a significant risk.
There are no specific guidelines on monitoring for adverse 
effects in sarcoidosis. Although serious adverse effects may 
occur without warning, some are potentially preventable by 
using the lowest steroid dose possible, careful monitoring, 
and appropriate prophylaxis. National formularies contain 
general prescribing information, and various professional 
organizations and charities provide patient information.
Evidence-based guidelines for preventing and treating 
osteoporosis have been published in several countries, 
mainly but not exclusively in Europe and North America.25 
Most address post-menopausal osteoporosis; a few deal with 
corticosteroid-induced osteoporosis.26–28 Adler and Hochberg 
have reviewed osteoporosis in men and sarcoidosis.26
The American College of Rheumatology (ACR) recom-
mends several interventions for preventing bone loss and 
fractures in patients taking prednisolone at a dose of 5 mg 
daily or more for over 3 months.27 Calcium and vitamin D 
supplementation (1500 mg/day and 800 IU/day respectively) 
is advised, as are bisphosphonates. Weekly preparations, such 
as alendronate 35 mg/week for prevention or 70 mg/week 
for treatment, or risedronate 35 mg/week for prevention or 
treatment, are preferred. These guidelines advise replacing 
gonadal steroids in men if deficient, and using calcitonin if 
bisphosphonates are contraindicated or not tolerated. They 
recommend annual follow-up and initiation of an exercise 
program where possible. They also advise 24-hour urinary 
calcium excretion estimation where the above measures are 
instituted because of the risk of hypercalcuria with glucocor-
ticosteroids. If substantial hypercalcuria is present (defined 
as calcium excretion exceeding 400 mg/day), the authors 
advise a thiazide diuretic with salt restriction.
UK guidelines on the management of glucocorticoid-
induced osteoporosis,28 endorsed by a number of national 
specialist medical societies including the BTS, advise mea-
surement of bone mineral density (BMD) to assess fracture 
risk in patients in whom there is a history of exposure to, 
or an intention to treat with, oral corticosteroids for three 
months or more. In those with a history of fracture, other 
secondary causes of osteoporosis should also be excluded. 
In those without a previous fracture and a T score above 0, 
reassurance and general measures are advised, and repeat 
BMD measurement is not indicated unless exceptionally 
high doses of glucocorticoids are required, as in for instance 
intravenous methyl prednisolone protocols.
If the T score is 0 to –1.5, general measures are advised 
and repeat bone density measurement in 1 to 3 years if 
steroids are continued. If the T score is –1.5 or lower, general 
measures and specific treatment are advised. General mea-
sures include reducing the steroid dose where possible and 
considering a steroid-sparing agent, nutritional advice with 
particular regard to calcium and vitamin D intake, regulating 
body weight, smoking cessation and avoiding alcohol excess, 
and assessing falls risk with further advice as appropriate. 
Specific treatments include alendronate, alfacalcidol, calci-
tonin, calctritiol, clodronate, cyclical etidronate, hormone 
replacement therapy, pamidronate and risedronate.
Adler and Hochberg address certain issues particularly 
relevant in sarcoidosis. Afro-Americans make up a large pro-
portion of the sarcoidosis population and may be at reduced 
risk of glucocorticoid-induced osteoporosis.26 However, since 
sarcoidosis can cause a vitamin D excess syndrome resulting 
from vitamin D activation in granulomas, hypercalcemia and 
hypercalcuria can occur and be made worse by supplementary 
calcium and vitamin D frequently recommended for other 
patients. These authors therefore advise measuring baseline 
serum and urine calcium and repeating measurements Therapeutics and Clinical Risk Management 2009:5 579
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4 to 8 weeks after starting calcium supplements, with 
subsequent monitoring. A study of BMD in women with 
sarcoidosis has shown that post-menopausal controls had 
higher BMD than untreated patients with sarcoidosis, sug-
gesting that post-menopausal patients with sarcoidosis may 
be at increased risk of bone mineral loss.29
First reported in 2003, hundreds of cases of bisphosphonate-
associated osteonecrosis of the mandible have now been 
described worldwide.30 This complication can arise spontane-
ously or follow an invasive procedure such as dental extraction. 
Most cases have been associated with intravenous pamridonate 
and zoledronic acid, and length of treatment is a further risk 
factor, especially over 36 months. An initial dental examination 
with appropriate preventative dentistry should be considered 
before starting; while patients with concomitant risk factors 
should avoid invasive dental procedures while on treatment 
if possible.
A further consideration in sarcoidosis is that patients are 
relatively young, with females often of reproductive age. 
Since manufacturers advise against using bisphosphonates 
in pregnancy, physicians must either not prescribe these 




A number of patients with severe or persistent sarcoidosis 
require treatment with alternative agents, usually in combina-
tion with corticosteroids but sometimes alone, either in those 
for whom corticosteroids are contra-indicated, or in those 
unable to tolerate the side-effects of steroids. The range of 
potential alternative immunosuppressive agents is wide and 
includes methotrexate, azathioprine, hydroxychloroquine, 
cyclophosphamide, mycophenolate mofetil, cyclosporin A, 
and chlorambucil, as well as agents which more specifically 
target TNFα, including pentoxifylline, thalidomide, inflix-
imab and etanercept. Most of the published literature examin-
ing these agents consists of small case series with significant 
potential for bias, and many have primarily investigated 
the effects of these agents on extra-pulmonary, rather than 
pulmonary, disease. Only the most commonly used agents 
are reviewed here.
Methotrexate
Methotrexate has been employed as a steroid-sparing agent 
for many years in the treatment of rheumatoid arthritis, and 
has recently emerged as one of the preferred second-line 
drugs for treating sarcoidosis. It is a folic acid analogue 
which inhibits dihydrofolate reductase and trans-methylation 
reactions. At low doses it has anti-inflammatory properties 
attributed largely to enhanced release of adenosine. Adenos-
ine suppresses TNFα release from monocytes, macrophages 
and neutrophils, suppresses neutrophil reactive oxygen 
species release, and inhibits lymphocyte proliferation. 
A randomized controlled trial of methotrexate (10 mg once 
weekly) or placebo plus oral prednisolone in 24 patients, 
conducted over 1 year, showed that patients taking metho-
trexate required significantly less prednisolone in the second 
6-month period.31 However, the study was limited by a high 
drop-out rate, only 15 patients remaining in the study after 
6 months, and methotrexate was no different to placebo on 
an intention-to-treat basis. Lung function, radiology and 
symptoms did not differ between the two groups.
Aside from teratogenicity, the major side-effects are 
hepatotoxicty and bone marrow suppression, and regular 
monitoring of liver function and full blood count is thus vital. 
There is uncertainty around the value of surveillance liver 
biopsy in patients exposed to methotrexate for prolonged 
periods. Many authors recommend co-treatment with folic 
acid to limit toxicity. A typical protocol is folic acid 5 to 10 mg 
once weekly, taken the day after methotrexate. Pregnancy 
should be excluded in females before starting treatment, 
and male and female patients receiving methotrexate must 
employ effective contraception. UK authorities advise con-
tinued contraception for at least three months after stopping 
the drug in males and females. North American advice is 
that pregnancy should be avoided for at least 3 months after 
treatment in male patients, and for at least one ovulatory cycle 
in females. Patients who experience troublesome systemic 
upset after taking the drug may benefit from dividing the once 
weekly dose into two twice weekly doses.
Azathioprine
Azathioprine is a purine analogue which has been shown in 
case series to improve chest x-ray appearances and breath-
lessness.32 Its exact mechanism of action is unclear, but it is 
converted to mercaptopurine, which affects RNA and DNA 
synthesis. Cellular immunity is suppressed to a greater degree 
than humoral immunity. There are no randomized controlled 
trials of azathioprine in sarcoidosis. A retrospective review 
suggested benefit in only 2 out of 10 patients,33 while an 
open study analyzing 11 patients with chronic sarcoidosis 
treated with both azathioprine and prednisolone did suggest 
benefit.34 All patients had significant symptomatic relief and 
showed improved radiographic and physiological parameters, 
without experiencing serious side-effects, despite reducing Therapeutics and Clinical Risk Management 2009:5 580
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their prednisolone dose to 0.1 mg/kg/day within two to three 
months of starting the study. Cytokine release in bronchoalve-
olar lavage was reduced. The authors commented that a larger 
study was required to answer definitively whether azathioprine 
might be an effective steroid-sparing agent in sarcoidosis; 
a decade later such a study remains to be conducted.
Regular blood counts to check for myelosuppression, 
and liver function monitoring, are essential in patients taking 
azathioprine. Azathioprine is metabolized by the enzyme 
thiopurine methyltransferase (TPMT), and the risk of myelo-
suppression is increased in the minority of the population 
who are homozygous for low TPMT activity. Consequently 
many authors advise testing for TPMT levels before starting 
azathioprine, despite a paucity of evidence to support this 
practice.35 Azathioprine should not generally be initiated dur-
ing pregnancy as there have been reports of premature birth 
and low birthweight after exposure; spontaneous abortion has 
been reported after maternal or paternal exposure.
Hydroxychloroquine
Hydroxychloroquine (like chloroquine) is an anti-malarial 
agent. Two randomized controlled trials have compared 
chloroquine and placebo in pulmonary sarcoidois.36,37 In the 
earlier British study, 52 patients who had not received 
steroids but either had pulmonary infiltrates for 6 months and 
breathlessness, or progressive lung infiltrates for 6 months, or 
persistent infiltrates for 1 year, were randomized to receive 
chloroquine or placebo for 16 weeks. Chloroquine treatment 
conferred no benefit and greater side-effects. In the recent, 
Canadian, study, 23 patients received chloroquine 750 mg 
daily for 6 months, gradually tapering every two months to 
250 mg daily. Eighteen patients were then randomized to 
a maintenance group or to an observation group. Patients 
randomized to the maintenance group had a slower decline 
in lung function and fewer relapses than those in the obser-
vation group. Side-effects were mainly limited to the high 
dose treatment phase. The authors conclude that chloroquine 
should be considered in chronic pulmonary sarcoidosis; in 
practice, hydroxychloroquine is preferred because it has 
lower ocular toxicity.
Hydroxychloroquine should be used with caution in liver 
or renal impairment, and regular blood count monitoring 
(to check for agranulocytosis and thrombocytopenia) and 
liver function is needed. The British Royal College of 
Ophthalmologists advises that patients should be asked about 
visual impairment before starting treatment, and that visual 
acuity should be measured and recorded. If eye disease is 
present, an ophthalmologist should be consulted before starting 
treatment. Patients should be asked about visual symptoms 
during treatment and visual acuity monitored annually. If 
treatment is required for over 5 years, individual arrangements 
should be made with the local ophthalmology service.
Hydroxychloroquine should be used in caution in 
glucose-6-phosphate (G6PD) deficiency as it may precipitate 
acute hemolytic anemia. As deficiency is highly prevalent 
in Africans, in whom persistent and severe sarcoidosis is 
more common, many physicians check G6PD levels before 
starting hydroxychloquine.
Cyclosporin A
Cyclosporin A is a T cell suppressor which has been reported 
to improve neurosarcoidosis in two retrospective studies. 
However, a randomized controlled trial in 37 patients with 
pulmonary sarcoidosis treated over 18 months showed no 
benefit in terms of breathlessness or lung function, and side-
effects were significantly greater in the treatment group.38 
Its use cannot therefore be recommended in pulmonary 
sarcoidosis.
Cyclophosphamide
Cyclophosphamide is an alkylating agent which has been 
used with apparent benefit in cardiac and neurosarcoidosis, 
but there are no controlled studies in pulmonary disease. 
Routine use cannot therefore be recommended.
Mycophenolate mofetil
Mycophenolate mofetil (MMF) is an antiproliferative 
immunosuppressant like azathioprine, but is metabolized 
to mycophenolic acid, which has a more selective action 
than azathioprine. Several authors report employing MMF 
successfully as a steroid-sparing agent in extra-pulmonary 
sarcoidosis, but there are no controlled studies in pulmonary 
disease, and there are therefore currently insufficient data to 
recommend its use.
TNFα inhibitors
Agents which more specifically target TNFα include 
thalidomide, pentoxifylline, infliximab and etanercept. 
Individual case reports and small series support the use of 
thalidomide in cutaneous sarcoidosis, but there are no studies 
in pulmonary disease. Teratogenic concerns strictly limit its 
drug in women of child-bearing age, and side-effects can be 
troublesome. Pentoxifylline in high doses has been shown to 
improve lung function in mild pulmonary sarcoidosis.39
The TNFα inhibitor infliximab was first reported to be 
useful in refractory cutaneous and pulmonary sarcoidosis Therapeutics and Clinical Risk Management 2009:5 581
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in 2001. Since then a series of case reports and small series 
have reported the effectiveness of infliximab for treating 
various manifestations, including skin, eye, brain, lung, 
sinus and muscle involvement. Two larger studies were 
reported in 2006. The first, by Doty and colleagues,40 was 
a retrospective study of ten patients with sarcoidosis refrac-
tory to conventional agents. Six patients had lung involve-
ment although the indication for using infliximab in these 
patients was extra-pulmonary disease. Nine patients reported 
symptomatic improvement with infliximab treatment, and 
all demonstrated objective evidence of improvement. In five 
of six patients taking concomitant corticosteroids the dose 
was reduced. The authors did not comment on lung function 
or radiology. They nevertheless concluded that infliximab 
appeared safe and effective in refractory sarcoidosis.
The second study, conducted by Baughman and 
colleagues,41 was a phase II, multi-center, double-blind, 
placebo-controlled clinical trial in which patients were 
randomized in a 1:1:1 ratio to receive intravenous placebo, 
infliximab 3 mg/kg, or infliximab 5 mg/kg at weeks 0,2,6,12, 
18 and 24. Patients were followed through to week 52. 
138 patients were randomized; 44 completed the placebo 
arm, 46 completed the infliximab 3 mg/kg arm and 45 patients 
completed the infliximab 5 mg/kg arm. In all cases the indica-
tion for entering the study was refractory pulmonary disease. 
Patients in the infliximab groups combined had a mean 
increase in forced vital capacity (FVC) of 2.5% predicted 
at week 24. Post-hoc exploratory analyses suggested that 
patients with more severe disease (longer disease duration, 
lower FVC or more symptoms) seemed to benefit the most.
Although these benefits appear modest, they would be 
significant in patients with life-threatening fibrotic disease who 
would potentially also be candidates for transplantation. Even 
stability in such patients represents a significant treatment 
response, and improvement would be exceptional.
Etanercept has not been found to be as effective in 
sarcoidosis, possibly because infliximab achieves greater 
tissue penetration and cell mediated lysis of TNF-secreting 
cells. Infliximab may therefore be considered in life-
threatening pulmonary sarcoidosis when all other options 
have been exhausted. It is expensive, and patients need careful 
assessment beforehand for evidence of tuberculosis.
Adverse effects  
of immunosuppression
Opportunistic infections are a potential consequence of 
immunosuppression. Prophylaxis against pneumonia caused 
by Pneumocystis jiroveci should be given to all patients 
with a history of the infection, and should be considered for 
severely immunocompromised patients. North American 
guidelines for preventing opportunistic infection in 
HIV-infected individuals,42 endorsed by the British Infection 
Society, provide the basis for current recommendations. 
Oral co-trimoxazole is the drug of choice for prophylaxis, 
either 960 mg daily or three times a week. The dose can be 
reduced to 480 mg daily to improve tolerance. In patients 
unable to tolerate co-trimoxazole, nebulized pentamidine 
is effective, as is oral dapsone; atovaquone has also been 
employed. Co-trimoxazole and dapsone can cause bone mar-
row suppression and skin rashes among other side-effects. 
Neither North American nor British sarcoidosis guidelines 
recommend pneumocystis prophylaxis routinely in otherwise 
immuno-competent patients.
Lung transplantation
A small number of patients with severe and progressive 
pulmonary sarcoidosis, despite exhaustive medical therapy, 
may be candidates for transplantation. Patients must be assessed 
for the potential presence of bronchiectasis, right ventricular 
impairment, infection, and mycetomas before proceeding.
Sarcoidosis patients represent around 3% of all transplant 
recipients in the USA.43,44 In these series patients with 
sarcoidosis were no more likely to die than those undergoing 
transplantation for other reasons. African-Americans, 
however, were nearly 50% more likely to die. Possible 
reasons include reduced access to healthcare before and 
after surgery, increased graft loss due to immunological 
hyper-responsiveness, and greater major histocompatibility 
polymorphism. Similar findings are reported in the setting 
of renal and liver transplantation.43
Small series report 1-year survival figures of 62% to 72% 
and 4- to 5-year survival of 46% to 56%.45,46 In 2008, the Inter-
national Society for Heart and Lung Transplantation reported 
on survival for 506 sarcoidosis patients transplanted between 
January 1990 and June 2006.44 Five-year survival was 51% 
and 10-year survival 31%. For comparison, 5- and 10-year 
survival in recipients with cystic fibrosis was 56% and 39%, 
and 45% and 21% respectively in recipients with idiopathic 
pulmonary fibrosis. Sarcoidosis is the most common disease 
to recur in transplanted lung, with reported recurrence rates 
of 35% to 62.5%,45,47 but appears to have a good prognosis, 
often being asymptomatic and self-limiting.
Current guidelines on sarcoidosis
A decade ago the American Thoracic Society (ATS), European 
Respiratory Society (ERS) and the World Association of Therapeutics and Clinical Risk Management 2009:5 582
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Sarcoidosis and Other Granulomatous Disorders (WASOG) 
jointly published a statement on sarcoidosis.1 There was 
agreement that steroids are effective short-term but it was 
also emphasized that it is not known whether they alter the 
natural history of the disease, or for how long treatment 
should continue. The authors concluded that patients with 
progressive symptomatic disease, or asymptomatic patients 
with infiltrates on CXR and progressively worsening lung 
function, should probably be treated.
The ATS/ERS/WASOG review suggests an initial dose of 
20 to 40 mg/day for pulmonary sarcoidosis, or the equivalent 
taken alternate days, and further evaluation of response 
after 1 to 3 months. In steroid responders it advises gradual 
tapering of the dose to 5 to 10 mg/day (or an equivalent alternate 
day dose), and treating for at least 12 months. It suggests that 
inhaled steroids may be of value in airway disease. In patients 
who fail to respond to steroids after three months, it suggests 
considering other reasons for failure such as the presence of 
irreversible fibrosis, noncompliance, or inadequate dosage.
The 2008 British Thoracic Society (BTS) interstitial lung 
disease (ILD)16 guidelines conclude that treatment is not indi-
cated for asymptomatic stage I disease, nor in asymptomatic 
patients with stage II or III disease with mild lung function 
abnormalities and stable parameters. They recommend oral 
corticosteroids as first-line therapy in patients with disease 
progression (as indicated by radiology or lung function) or 
significant symptoms. The authors recommend an initial 
dose of 0.5 mg/kg/day for 4 weeks, subsequently reduced to 
a maintenance dose which controls symptoms and disease 
progression, for a period of 6 to 24 months. Inhaled steroids 
are not recommended as initial or maintenance treatment, 
but may be considered for symptom control in patients with 
troublesome cough. Table 2 summarizes the main points 
from the two guidelines.
Bisphosphonates are advised as appropriate to minimize 
steroid-induced osteoporosis. Alternative immunosuppressants 
are recommended when corticosteroids are not controlling the 
disease or when side effects are intolerable, with methotrexate 
the agent of choice. Since low carbon monoxide transfer 
factor (TLCO) measurements predict survival in interstitial 
lung disease, they are a useful guide to the timing of refer-
ral for lung transplantation. British guidelines recommend 
that patients with end-stage pulmonary disease and a TLCO 
of 39% predicted should be considered by the regional 
transplant center.
In summary, there is agreement that oral corticosteroids 
should be considered in patients with severe, persistent or 
progressively worsening respiratory symptoms, or declining 
lung function. Severe symptoms are those which interfere 
with essential aspects of the patient’s daily life, such as 
work or caring for young children. Many physicians would 
monitor lung function (VC and TLCO) for 6 months before 
deciding that there is progressive deterioration. There 
are no absolute cut-offs to determine when treatment is 
necessary, but most clinicians would regard a fall in VC of 
10% to 15% and/or TLCO of 20%, confirmed more than 
once, as significant. There is agreement that neither oral 
nor inhaled corticosteroids are indicated in asymptomatic 
patients in the absence of other organ involvement.
The initial dose of oral prednisolone recommended by 
the ATS/ERS/WASOG guidelines is 20 to 40 mg daily; BTS 
guidelines suggest a slightly higher dose of 0.5 mg/kg/day. 
ATS/ERS/WASOG guidelines recommend further evaluation 
after one to three months; BTS guidelines advise review 
after 4 weeks. There is agreement that, provided the patient 
responds, the dose should then be reduced gradually to a 
maintenance dose.
ATS/ERS/WASOG guidelines suggest 5 to 10 mg 
daily as maintenance (or an equivalent alternate day dose) 
while BTS guidelines suggest a maintenance dose which 
will control symptoms and disease progression. ATS/ERS/
WASOG guidelines advise treating for at least 1 year.
Table 2 Summary of current guidelines for treatment of sarcoidosis





Progressive symptomatic disease, 
or asymptomatic with infiltrates on 
CXR and worsening lung function
20–40 mg for 1–3 months before weaning 5–10 mg for at least 1 year May be useful in 
airway disease
BTS Disease progression as indicated 
by radiology or lung function, or 
significant symptoms
0.5 mg/kg for 4 weeks before weaning As required to control 
symptoms and disease 





Abbreviations: ATS, American Thoracic Society; eRS, european Respiratory Society;   wASOG, world Association of Sarcoidosis and Other Granulomatous Disorders; 
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ATS/ERS/WASOG guidelines suggest that inhaled 
steroids may be of value in airway disease. BTS recom-
mendations do not advise inhaled steroids as initial or 
maintenance treatment, but suggest they may have a place 
in managing selected patients to control cough.
With  regard  to  monitoring  for  adverse  effects, 
potentially serious side-effects are well recognized and the 
principles used in other clinical settings generally apply. 
National evidence-based guidelines for the prevention 
of steroid-induced osteoporosis provide valuable advice. 
Physicians may however wish to avoid prescribing calcium 
and vitamin D supplements in patients with sarcoidosis unless 
they also monitor serum and urine calcium levels. The dose 
of calcium and vitamin D can then be tailored according to 
these parameters. With bisphosphonates, clinicians should 
be aware of the risk of osteonecrosis of the mandible and be 
ready to advise patients to have an initial dental examination 
and appropriate preventive dentistry. When treating females 
of child-bearing age, they should also be aware that these 
agents are not recommended in pregnancy.
Current British ILD guidelines recommend considering 
other immunosuppressive agents when corticosteroids are not 
controlling the disease, or when side-effects are unacceptable, 
with methotrexate the agent of choice. Lung transplantation 
should be considered in end-stage pulmonary sarcoidosis.
Conclusions
Sarcoidosis is the commonest ILD and is often managed by 
respiratory specialists. Despite experience of over 50 years 
using oral corticosteroids, their long-term benefits remain 
unclear, as is the value of inhaled corticosteroids. General 
management strategies include clear patient information and 
smoking cessation advice. Pulmonary rehabilitation, oxygen 
supplementation and palliative care may be appropriate 
in patients with severe pulmonary fibrosis. International 
guidelines recommend oral steroids in those with severe or 
worsening symptoms and/or infiltrates on CXR. There is 
broad agreement on the initial dose, subsequent tapering and 
length of treatment. Monitoring for adverse effects requires 
particular attention to steroid-induced osteoporosis. National 
guidance is usually applicable but physicians should be 
aware of individual patients’ circumstances and may wish to 
amend advice accordingly. Alternative immunosuppressant 
agents and lung transplantation remain options for patients 
with severe disease.
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